Comparative Humoral and Cellular Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-adjuvanted Vaccine and HPV-6/11/16/18 Vaccine in Healthy Women Aged 18-45 Years: Follow-up Through Month 48 in a Phase III Randomized Study

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2014 Dec 9

PMID 25483700

Citations 37

Authors

Mark H Einstein

Myron J Levin

Archana Chatterjee

Nahida Chakhtoura

Peter Takacs

Gregory Catteau

Francis J Dessy

Philippe Moris

Lan Lin

Frank Struyf

Gary Dubin

Affiliations

Soon will be listed here.

Abstract

We previously reported higher anti-HPV-16 and -18 immune responses induced by HPV-16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after completion of full vaccination series) in women aged 18-45 y in an observer-blind study NCT00423046; the differences of immune response magnitudes were maintained up to Month 24. Here we report follow-up data through Month 48. At Month 48, in according-to-protocol cohort for immunogenicity (seronegative and DNA-negative for HPV type analyzed at baseline), geometric mean titers of serum neutralizing antibodies were 2.0- to 5.2-fold higher (HPV-16) and 8.6- to 12.8-fold higher (HPV-18) in HPV-16/18 vaccine group than in HPV-6/11/16/18 vaccine group. The majority of women in both vaccine groups remained seropositive for HPV-16. The same trend was observed for HPV-18 in HPV-16/18 vaccine group; however, seropositivity rates in HPV-6/11/16/18 vaccine group decreased considerably, particularly in the older age groups. In the total vaccinated cohort (regardless of baseline serological and HPV-DNA status), anti-HPV-16 and -18 neutralizing antibody levels induced by HPV-16/18 vaccine were higher than those induced by HPV-6/11/16/18 vaccine. CD4+ T-cell response for HPV-16 and HPV-18 was higher in HPV-16/18 vaccine group than in HPV-6/11/16/18 vaccine group. Memory B-cell responses appeared similar between vaccine groups. Both vaccines were generally well tolerated. Overall, the higher immune response observed with the HPV-16/18 vaccine was maintained up to Month 48. A head-to-head study incorporating clinical endpoints would be required to confirm whether the observed differences in immune response between the vaccines influence the duration of protection they provided.

Citing Articles

The Non-inferiority of Human Papillomavirus Vaccine Immunogenicity Among Women Over 26 Years: A Systematic Review.

Andijani O, Alsalhi S Cureus. 2024; 16(7):e65157.

PMID: 39176354 PMC: 11339578. DOI: 10.7759/cureus.65157.

Current status and future directions for the development of human papillomavirus vaccines.

Wang R, Huang H, Yu C, Li X, Wang Y, Xie L Front Immunol. 2024; 15:1362770.

PMID: 38983849 PMC: 11231394. DOI: 10.3389/fimmu.2024.1362770.

Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV.

Losada C, Samaha H, Scherer E, Kazzi B, Khalil L, Ofotokun I Vaccines (Basel). 2023; 11(6).

PMID: 37376456 PMC: 10301114. DOI: 10.3390/vaccines11061067.

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.

Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P NPJ Vaccines. 2023; 8(1):39.

PMID: 36922512 PMC: 10017795. DOI: 10.1038/s41541-023-00628-8.

B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination.

Prabhu P, Carter J, Galloway D Vaccines (Basel). 2022; 10(6).

PMID: 35746445 PMC: 9229470. DOI: 10.3390/vaccines10060837.

References

Moscicki A, Wheeler C, Romanowski B, Hedrick J, Gall S, Ferris D . Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012; 31(1):234-41. DOI: 10.1016/j.vaccine.2012.09.037. View

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1359-73. PMC: 3338933. DOI: 10.4161/hv.7.12.18282. View

Romanowski B, Schwarz T, Ferguson L, Ferguson M, Peters K, Dionne M . Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014; 10(5):1155-65. PMC: 4896558. DOI: 10.4161/hv.28022. View

Einstein M, Takacs P, Chatterjee A, Sperling R, Chakhtoura N, Blatter M . Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 2014; 10(12):3435-45. PMC: 4514070. DOI: 10.4161/hv.36121. View

Winer R, Lee S, Hughes J, Adam D, Kiviat N, Koutsky L . Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157(3):218-26. DOI: 10.1093/aje/kwf180. View

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447):1757-65. DOI: 10.1016/S0140-6736(04)17398-4. View

Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F . Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. DOI: 10.1016/j.vaccine.2006.06.005. View

Villa L, Costa R, Petta C, Andrade R, Paavonen J, Iversen O . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11):1459-66. PMC: 2360730. DOI: 10.1038/sj.bjc.6603469. View

10.

Olsson S, Villa L, Costa R, Petta C, Andrade R, Malm C . Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25(26):4931-9. DOI: 10.1016/j.vaccine.2007.03.049. View

11.

Paavonen J, Jenkins D, Bosch F, Naud P, Salmeron J, Wheeler C . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580):2161-2170. DOI: 10.1016/S0140-6736(07)60946-5. View

12.

Partridge J, Hughes J, Feng Q, Winer R, Weaver B, Xi L . Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis. 2007; 196(8):1128-36. DOI: 10.1086/521192. View

13.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

14.

Dessy F, Giannini S, Bougelet C, Kemp T, David M, Poncelet S . Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer.... Hum Vaccin. 2008; 4(6):425-34. DOI: 10.4161/hv.4.6.6912. View

15.

. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25 Suppl 3:C1-230. DOI: 10.1016/S0264-410X(07)01183-8. View

16.

Schwarz T, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P . Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine. 2008; 27(4):581-7. DOI: 10.1016/j.vaccine.2008.10.088. View

17.

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

18.

Castellsague X, Schneider A, Kaufmann A, Bosch F . HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009; 115(3 Suppl):S15-23. DOI: 10.1016/j.ygyno.2009.09.021. View

19.

Romanowski B, de Borba P, Naud P, Roteli-Martins C, De Carvalho N, Teixeira J . Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374(9706):1975-85. DOI: 10.1016/S0140-6736(09)61567-1. View

20.

Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K . An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. J Immunol Methods. 2010; 358(1-2):56-65. DOI: 10.1016/j.jim.2010.03.009. View